Date: April, 29, 2021

Your Name: Mostafa Elfawal

Manuscript Title: Artemisia annua and artemisinins are ineffective against human Babesia microti and

six Candida sp.

Manuscript number (if known): LCM-21-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | X None   |   |

| 1    |  | Ţ                         |                 |
|------|--|---------------------------|-----------------|
|      |  |                           |                 |
|      |  |                           |                 |
| 5    | Payment or honoraria for                     | XNone                     |                 |
|      | lectures, presentations,                     |                           |                 |
|      | speakers bureaus,                            |                           |                 |
|      | manuscript writing or                        |                           |                 |
|      | educational events                           |                           |                 |
| 6    | Payment for expert                           | XNone                     |                 |
|      | testimony                                    |                           |                 |
|      |  |                           |                 |
| 7    | Support for attending meetings and/or travel | XNone                     |                 |
|      | meetings and/or traver                       |                           |                 |
|      |  |                           |                 |
| 8    | Patents planned, issued or                   | X None                    |                 |
| 0    | pending                                      | XNOTIE                    |                 |
|      |  |                           |                 |
|      |  |                           |                 |
| 9    | Participation on a Data                      | XNone                     |                 |
|      | Safety Monitoring Board or                   |                           |                 |
|      | Advisory Board                               |                           |                 |
| 10   | Leadership or fiduciary role                 | XNone                     |                 |
|      | in other board, society,                     |                           |                 |
|      | committee or advocacy                        |                           |                 |
|      | group, paid or unpaid                        |                           |                 |
| 11   | Stock or stock options                       | XNone                     |                 |
|      |  |                           |                 |
|      |  |                           |                 |
| 12   | Receipt of equipment,                        | X_None                    |                 |
|      | materials, drugs, medical                    |                           |                 |
|      | writing, gifts or other                      |                           |                 |
|      | services                                     |                           |                 |
| 13   | Other financial or non-                      | XNone                     |                 |
|      | financial interests                          |                           |                 |
|      |  |                           |                 |
|      |  |                           |                 |
|      |  |                           |                 |
| Dlas | as summarias the shous so                    | uflick of interest in the | fallaction have |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

Date: April 27, 2021 Your Name: Olivia Gray

Manuscript Title: Artemisia annua and artemisinins are ineffective against human Babesia microti and

six Candida sp.

Manuscript number (if known): LCM-21-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| Δ | Consulting fees   | X None   |   |

| _   |   |                               |              |  |
|-----|---|-------------------------------|--------------|--|
| 5   | Payment or honoraria for lectures, presentations,                               | XNone                         |              |  |
|     | speakers bureaus,   |                               |              |  |
|     | manuscript writing or   |                               |              |  |
|     | educational events  |                               |              |  |
| 6   | Payment for expert  | XNone                         |              |  |
|     | testimony   |                               |              |  |
| -   | C 1 C 11 II   | V N                           |              |  |
| 7   | Support for attending meetings and/or travel                                    | XNone                         |              |  |
|     |   |                               |              |  |
|     |   |                               |              |  |
| 8   | Patents planned, issued or  | XNone                         |              |  |
|     | pending   |                               |              |  |
|     |   |                               |              |  |
| 9   | Participation on a Data   | XNone                         |              |  |
|     | Safety Monitoring Board or  |                               |              |  |
| 10  | Advisory Board  |                               |              |  |
| 10  | Leadership or fiduciary role  | XNone                         |              |  |
|     | in other board, society, committee or advocacy                                  |                               |              |  |
|     | group, paid or unpaid   |                               |              |  |
| 11  | Stock or stock options  | X None                        |              |  |
|     | ·   |                               |              |  |
|     |   |                               |              |  |
| 12  | Receipt of equipment,   | X_None                        |              |  |
|     | materials, drugs, medical   |                               |              |  |
|     | writing, gifts or other   |                               |              |  |
|     | services  |                               |              |  |
| 13  | Other financial or non-   | XNone                         |              |  |
|     | financial interests   |                               |              |  |
|     |   |                               |              |  |
|     |   |                               |              |  |
| Ple | ease summarize the above c  | onflict of interest in the fo | llowing box: |  |
|     | None.   |                               |              |  |
|     |   |                               |              |  |
|     |   |                               |              |  |
|     |   |                               |              |  |
|     |   |                               |              |  |
| Ple | Please place an "X" next to the following statement to indicate your agreement: |                               |              |  |

Date: 04/21/2021

Your Name: Claire Dickson-Burke

Manuscript Title: Artemisia annua and artemisinins are ineffective against human Babesia microti and

six Candida sp.

Manuscript number (if known): LCM-21-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   |   | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | XNone  |   |
| 3 | Royalties or licenses   | XNone  |   |
| 4 | Consulting fees   | X None   |   |

| 1    |  | Ţ                         |                 |
|------|--|---------------------------|-----------------|
|      |  |                           |                 |
|      |  |                           |                 |
| 5    | Payment or honoraria for                     | XNone                     |                 |
|      | lectures, presentations,                     |                           |                 |
|      | speakers bureaus,                            |                           |                 |
|      | manuscript writing or                        |                           |                 |
|      | educational events                           |                           |                 |
| 6    | Payment for expert                           | XNone                     |                 |
|      | testimony                                    |                           |                 |
|      |  |                           |                 |
| 7    | Support for attending meetings and/or travel | XNone                     |                 |
|      | meetings and/or traver                       |                           |                 |
|      |  |                           |                 |
| 8    | Patents planned, issued or                   | X None                    |                 |
| 0    | pending                                      | XNOTIE                    |                 |
|      |  |                           |                 |
|      |  |                           |                 |
| 9    | Participation on a Data                      | XNone                     |                 |
|      | Safety Monitoring Board or                   |                           |                 |
|      | Advisory Board                               |                           |                 |
| 10   | Leadership or fiduciary role                 | XNone                     |                 |
|      | in other board, society,                     |                           |                 |
|      | committee or advocacy                        |                           |                 |
|      | group, paid or unpaid                        |                           |                 |
| 11   | Stock or stock options                       | XNone                     |                 |
|      |  |                           |                 |
|      |  |                           |                 |
| 12   | Receipt of equipment,                        | X_None                    |                 |
|      | materials, drugs, medical                    |                           |                 |
|      | writing, gifts or other                      |                           |                 |
|      | services                                     |                           |                 |
| 13   | Other financial or non-                      | XNone                     |                 |
|      | financial interests                          |                           |                 |
|      |  |                           |                 |
|      |  |                           |                 |
|      |  |                           |                 |
| Dlas | as summarias the shous so                    | uflick of interest in the | fallaction have |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

Date: April 29, 2021

Your Name: Pamela J. Weathers

Manuscript Title: Artemisia annua and artemisinins are ineffective against human Babesia microti and

six Candida sp.

Manuscript number (if known): LCM-21-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution)  |
|---|---|--|--|
|   |   | Time frame: Since the initial  | planning of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | Yes Yes Yes  | NIH NCCIH Grants to generally support our work on Artemisia & referenced in the manuscript  WPI-U MA Med School Joint grant from both universities to help support the initial animal work & referenced in the manuscript.  See item #2 below. |
|   |   | Time frame: past   | 36 months  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | Yes<br>Yes<br>Yes  | Atelier temenos LLC: contract for Artemisia analyses.  IDAY: contract for Artemisia analyses.  La Maison d' Artemisia: Postdoctoral fellowship support.  |
| 3 | Royalties or licenses   | XNone  |  |
| 4 | Consulting fees   | XNone  |  |

| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone      |   |
|----|--|------------|---|
| 6  | Payment for expert testimony   | XNone      |   |
| 7  | Support for attending meetings and/or travel   | Yes        | From my NIH grants to attend an annual meeting.   |
| 8  | Patents planned, issued or pending   | XNone      |   |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                                      | XNone      |   |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid   | Yes<br>Yes | Associate Editor: Plant Cell issue Organ culture  Associate Editor: In Vitro Cell & Developmental Biology Plant Associate Editor: Molecules (Medicinal Chemistry Section) |
| 11 | Stock or stock options   | XNone      |   |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | XNone      |   |
| 13 | Other financial or non-<br>financial interests   | XNone      |   |

The author receives Federal and institutional grants, contract fees, and does editorial work for 3 journals. None of the above activities related to the present submitted manuscript.

### Please place an "X" next to the following statement to indicate your agreement:

Date: April 29, 2021

Your Name: Stephen M. Rich

Manuscript Title: Artemisia annua and artemisinins are ineffective against human Babesia microti and

six Candida sp.

Manuscript number (if known): LCM-21-2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution)  |
|---|---|--|--|
|   |   | Time frame: Since the initial  | planning of the work   |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | Center for Clinical and<br>Translational Science<br>(UMassMed/NIH)                           | Co- Investigator, CTTS –UMass Med (PI: P. Weathers) 01-Jan-11 to 12-Dec-12  "A novel antimalarial strategy based on whole plant delivery of Artemisia annua L."  Major goal: Demonstrate killing of rodent malaria parasites (P. chabaudi) in infected mice by feeding dried Artemisia annua. Parasitological and toxicological results are compared with those using pure artemisinin drug. |
|   |   | Time frame: past   | 36 months  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | _XNone   |  |
| 3 | Royalties or licenses   | XNone  |  |
| 4 | Consulting fees   | XNone  |  |

| 5  | Payment or honoraria for lectures, presentations, | XNone  |  |
|----|---|--------|--|
|    |   |        |  |
|    | speakers bureaus,                                 |        |  |
|    | manuscript writing or                             |        |  |
|    | educational events                                |        |  |
| 6  | Payment for expert                                | XNone  |  |
|    | testimony   |        |  |
|    |   |        |  |
| 7  | Support for attending meetings and/or travel      | XNone  |  |
|    | -   |        |  |
|    |   |        |  |
| 8  | Patents planned, issued or                        | XNone  |  |
|    | pending   |        |  |
|    |   |        |  |
| 9  | Participation on a Data                           | XNone  |  |
|    | Safety Monitoring Board or                        |        |  |
|    | Advisory Board                                    |        |  |
| 10 | Leadership or fiduciary role                      | XNone  |  |
|    | in other board, society,                          |        |  |
|    | committee or advocacy                             |        |  |
|    | group, paid or unpaid                             |        |  |
| 11 | Stock or stock options                            | XNone  |  |
|    |   |        |  |
| 12 | Descript of any i                                 | V News |  |
| 12 | Receipt of equipment,                             | _XNone |  |
|    | materials, drugs, medical writing, gifts or other |        |  |
|    | services  |        |  |
| 13 | Other financial or non-                           | X None |  |
| 13 | financial interests                               |        |  |
|    | inianical interests                               |        |  |
|    |   |        |  |
|    |   |        |  |

| The author receives grant from Center for the Clinical and Translational Science (UMassMed/NIH) . |
|---|
|   |

Please place an "X" next to the following statement to indicate your agreement: